Loading clinical trials...
Loading clinical trials...
A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Conditions
Interventions
BG1805
Locations
3
China
ZhuJiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Start Date
March 7, 2024
Primary Completion Date
March 1, 2027
Completion Date
July 1, 2027
Last Updated
April 17, 2025
NCT06852222
NCT06580106
NCT06501196
NCT06384261
NCT06382168
NCT06643962
Lead Sponsor
Guangzhou Bio-gene Technology Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions